Senolytics: promise and reality

In our body there are cells that stop dividing but do not disappear. They are known as senescent cells.

In small amounts they can be useful: they take part in tissue repair, in certain protective mechanisms against tumors and in other biological processes. The problem appears when, with age, they begin to accumulate and remain in tissues for longer. Current research links this accumulation to chronic inflammation, fibrosis and various age-related diseases.

This is where the idea of senolytics comes from: substances designed to selectively eliminate certain senescent cells.

Why can these cells be problematic?

A senescent cell does not just stop dividing. It can also release inflammatory molecules, growth factors and other signals capable of altering the environment around it.

This set of signals is known as SASP, senescence-associated secretory phenotype.

These molecules can affect neighboring cells and help sustain a state of chronic inflammation. That is why senescent cells are now studied not only as a consequence of aging, but also as one of its possible mechanisms.

With age, moreover, the immune system may become less effective at recognizing and eliminating these cells, which favors their accumulation.

What are senolytics?

Senolytics are experimental drugs or compounds that try to exploit certain vulnerabilities of senescent cells to induce their elimination, while trying to harm healthy cells as little as possible.

Among the first and most studied combinations are dasatinib and quercetin. Over time many other candidates have appeared, including approaches based on small molecules, immunotherapy and cell-based technologies.

The logic is attractive:

if we manage to eliminate some of the cells that contribute to inflammation and tissue deterioration, perhaps we can improve tissue function.

But a promising hypothesis is not yet the same as a proven therapy.

Why do they generate so much interest?

In animal models, the results have been striking.

Eliminating certain senescent cells has managed to improve some functional parameters and reduce manifestations of certain age-related conditions.

These results gave strong momentum to longevity research and led to the first clinical trials in humans.

But there is an essential difference here: what works in animals cannot be automatically transferred to people.

What do we know in humans?

Senolytics have already been tested in small clinical studies related to specific diseases and conditions.

Some studies have shown changes in biomarkers and preliminary signs of possible benefit. However, there is still no solid evidence that senolytics produce a clear and generalized clinical benefit in humans.

Today it cannot be claimed that senolytics:

• demonstrably slow human aging;
• increase life expectancy;
• rejuvenate the body;
• prevent age-related diseases in healthy people.

These claims go beyond the available evidence.

The main problem: not all senescent cells are the same

One of the most important discoveries of recent years is that senescent cells are very heterogeneous.

They can behave differently depending on:

• the tissue;
• the cell type;
• the cause of senescence;
• age;
• the specific disease.

That is why a drug that works well on one type of senescent cell may be much less effective on another.

This is one of the reasons why researchers increasingly speak of personalized senolytic strategies, rather than a single universal treatment.

Should we eliminate all senescent cells?

No.

Cellular senescence also serves beneficial functions. It takes part in wound repair, in the control of damaged cells and in certain antitumor mechanisms.

Therefore, the goal cannot be simply to “clean” the body of all senescent cells.

The real difficulty lies in identifying which cells are harmful, in which tissue and at what moment.

Selectivity is one of the greatest challenges of this area of research.

Senolytics and supplements are not the same thing

The word “senolytic” is increasingly appearing in supplement advertising.

But the fact that a substance is studied in the laboratory does not mean that a commercial supplement has a proven anti-aging effect.

Quercetin, for example, is studied in some experimental strategies, but that does not automatically turn any quercetin supplement into an effective anti-age therapy.

A plausible biological mechanism is not the same as a proven clinical benefit.

Where research is heading

Several strategies are currently being investigated:

• more selective senolytics;
• senomorphics, which do not eliminate the cells but reduce their harmful signals;
• immunological treatments that help the body better recognize senescent cells;
• targeted delivery systems aimed at specific tissues.

It is possible that future therapies will be much more precise than the first experimental senolytics.

So, can we “eliminate aged cells” today?

The idea has a solid scientific basis and is one of the most interesting lines of the biology of aging.

But, for now, senolytics remain an experimental field, not a standard treatment to slow aging in healthy people.

What is truly relevant is the change of approach they represent.

Instead of treating only individual diseases once they have already appeared, science is trying to understand and, in the future, intervene in common biological mechanisms that take part in multiple age-related processes.

If these strategies prove their efficacy and safety, they could open a new stage in longevity medicine.

But today there is still an important distance between promising biology and a truly proven anti-aging therapy.